Related Experiment Video
Updated: Feb 6, 2026
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy
Siqing Fu1, Yudong Wang1,2, Khandan Keyomarsi3
1a Department of Investigational Cancer Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Introduction:
Wee1 kinase controls the G2-M checkpoint. Wee1 inhibition by AZD1775 allows cells with a deregulated G1 checkpoint to progress, resulting in catastrophe and apoptosis. The challenges ahead are in the establishment of the optimum dosing schedule either alone or in combination and the identification of patients with specific biomarker profiles who benefit most.
Areas Covered:
This article provides an overview of AZD1775, based on English peer-reviewed articles on MEDLINE. The authors highlight the data from the published preclinical and clinical studies.
Expert Opinion:
A majority of the current clinical trials focus on AZD1775 combined with chemotherapy or radiation. Treatment with AZD1775 was tolerated, and antitumor activity has been observed, especially in patients with advanced malignancies harboring G1 checkpoint aberrations and/or DNA damage repair defects. Thus, identification of the molecular subtypes that benefit most from the treatment with AZD1775 alone or in combination may provide a novel strategy for cancer therapy. Research is needed for devising regimens to explore AZD1775 in combination with biologically targeted agents and/or immunotherapy (low dose vs. high dose, intermittent vs. continuous, sequential vs. concurrent, etc.) for identifying potential biomarkers predictive of response and survival.
Insights
AZD1775, a Wee1 kinase inhibitor, shows promise in treating advanced cancers by causing cell catastrophe. Further research is needed to optimize dosing and identify patient biomarkers for effective cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Cycle Regulation
Background:
- Wee1 kinase is crucial for the G2-M cell cycle checkpoint.
- AZD1775 inhibits Wee1 kinase, leading to cell death in cancer cells with G1 checkpoint defects.
- Understanding AZD1775's role in cancer therapy is critical.
Purpose of the Study:
- To provide an overview of AZD1775 based on published preclinical and clinical data.
- To highlight the potential of AZD1775 in cancer treatment strategies.
- To identify challenges and future research directions for AZD1775.
Main Methods:
- Review of English peer-reviewed articles on MEDLINE.
- Analysis of preclinical and clinical study data for AZD1775.
- Synthesis of current research findings and expert opinions.
Main Results:
- AZD1775 is generally well-tolerated and demonstrates antitumor activity in advanced malignancies.
- Patients with G1 checkpoint aberrations and DNA repair defects show particular benefit.
- Combination therapies (chemotherapy, radiation) are a focus of current clinical trials.
Conclusions:
- AZD1775 represents a potential novel strategy for cancer therapy, particularly in combination regimens.
- Identifying predictive biomarkers is essential for patient selection and treatment optimization.
- Further research is required to determine optimal dosing schedules and combinations with targeted agents or immunotherapy.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
02:54Protein Kinases and Phosphatases
01:12Strategies of Self-Presentation I: Strategic Self-Presentation
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...